Vertex Pharmaceuticals Incorporated
General ticker "VRTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $113.8B (TTM average)
Vertex Pharmaceuticals Incorporated does not follow the US Stock Market performance with the rate: -14.0%.
Estimated limits based on current volatility of 1.4%: low 472.41$, high 485.59$
Factors to consider:
- Earnings expected soon, date: 2026-02-09 bmo
- Company included in S&P500 list
- Company included in NASDAQ-100 index
- Total employees count: 6100 as of 2024
- US accounted for 60.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Inability to develop and commercialize products, Inability to scale operations, Foreign operations risks, Cybersecurity threats, Strategic risks and growth management
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [399.76$, 575.61$]
- 2025-12-31 to 2026-12-31 estimated range: [441.15$, 625.40$]
Financial Metrics affecting the VRTX estimates:
- Negative: with PPE of 1408.6 at the end of fiscal year the price was high
- Negative: Operating cash flow per share per price, % of -0.47 <= 0
- Positive: -5.04 < Operating profit margin, % of -2.07
- Negative: -0.18 < Industry inventory ratio change (median), % of 0
- Negative: Industry earnings per price (median), % of -16.05 <= 0
- Negative: negative Industry operating cash flow (median)
- Negative: 0.01 < Interest expense per share per price, % of 0.03
- Negative: Shareholder equity ratio, % of 72.82 > 64.37
- Positive: -4.43 < Investing cash flow per share per price, % of -3.58
Short-term VRTX quotes
Relationship graph
Long-term VRTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $8,930.70MM | $9,869.20MM | $11,020.10MM |
| Operating Expenses | $4,623.30MM | $6,037.20MM | $11,253.00MM |
| Operating Income | $4,307.40MM | $3,832.00MM | $-232.90MM |
| Non-Operating Income | $-75.00MM | $547.80MM | $481.40MM |
| Interest Expense | $54.80MM | $44.10MM | $30.60MM |
| R&D Expense | $2,540.30MM | $3,162.90MM | $3,630.30MM |
| Income(Loss) | $4,232.40MM | $4,379.80MM | $248.50MM |
| Taxes | $910.40MM | $760.20MM | $784.10MM |
| Profit(Loss)* | $3,322.00MM | $3,619.60MM | $-535.60MM |
| Stockholders Equity | $13,912.70MM | $17,580.40MM | $16,409.60MM |
| Inventory | $460.60MM | $738.80MM | $1,205.40MM |
| Assets | $18,150.90MM | $22,730.20MM | $22,533.20MM |
| Operating Cash Flow | $4,129.90MM | $3,537.30MM | $-492.60MM |
| Capital expenditure | $204.70MM | $258.40MM | $297.70MM |
| Investing Cash Flow | $-321.10MM | $-3,141.70MM | $-3,770.00MM |
| Financing Cash Flow | $-67.70MM | $-562.20MM | $-1,494.90MM |
| Earnings Per Share** | $12.97 | $14.05 | $-2.08 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.